🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Former police officer Gregory McMichael and his son Travis McMichael who murdered #AhmaudArbery for jogging while Black. No one has been charged and this case is being covered up. This is why #Kaepernick took a knee #justiceforahmaud #BlackLivesMatter

I just took action on Action Network: Join The Movement. Take action here: actionnetwork.org/forms/join-the…

Every day, but especially during ALS Awareness Month, we recognize the patients, families, caregivers, advocates, researchers and clinicians whose determination and resilience inspire hope for improved treatment options and eventually a cure.

Our co-founder and director of R&D presented in vivo imaging data with our HDAC6 PET imaging tool to quantifiably demonstrate target occupancy with our novel next-gen HDAC6 inhibitor drug candidates at #NRM2024 last weekend. More to come! linkedin.com/feed/update/ur…

And that's a wrap on #BIO2024! Our CEO, Rick Lundberg, spent a busy few days meeting with #biotech & #pharma industry partners and investors while still making time to enjoy some of the sights in beautiful San Diego.

Eikonizo's Rebecca James had a steady stream of highly engaged visitors during her poster presentation on next-generation HDAC6 inhibitors for #ParkinsonsDisease at the Keystone Symposium for Neurodegenerative Diseases in Santa Fe last week.  More to come! #KSNeurodegen24

The Eikonizo Therapeutics team is getting ready for the European Network to Cure #ALS (#ENCALS) 2024 Annual Meeting in Stockholm next week! Stop by our posters to learn more about our science & the exciting work we have underway for the treatment of #neurodegenerativediseases, including #ALS

Eikonizo Therapeutics team are in Stockholm this week presenting important new research highlighting our highly selective CNS-penetrant HDAC6i for #ALS, and our novel HDAC6 PET tracer to measure in vivo target engagement. Lots of interest at our ENC ALS 2024 poster sessions. Onward!

We're back from #ENCALS2024 and more energized than ever! What a great opportunity to meet with members of the #ALS community representing academia, industry and advocacy, and discuss our innovative research programs underway. We also enjoyed the The Vasa Museum gala.

Eikonizo Therapeutics is excited to be in Philly for the Alzheimer's Association #AAIC24. A great opportunity to learn from and meet with some of the best and brightest in dementia research. If you see our CEO Rick Lundberg, be sure to stop and say hello!

Eikonizo Therapeutics was proud to sponsor the Live Like Lou biennial #ALS Research Symposium, bringing together early-career researchers from far and wide to advance #ALSresearch.

We’re thrilled to announce an investment by Novo Nordisk which will support development of our lead candidate EKZ-102 for ALS and enable the advancement of our novel HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease. businesswire.com/news/home/2024…

Today is #NationalWearRedDay established by American Heart Association to raise awareness of #CardiovasularDisease – the #1 killer of women. DYK, according to @ACC women are at higher risk of #HFpEF, a type of heart failure with limited effective treatment options, than men? GoRedforWomen